Introduction
SmarterDx is a New York-based healthcare technology company founded in 2020 that applies proprietary clinical artificial intelligence to hospital revenue integrity — identifying documentation gaps before claims submit and generating evidence-backed payer appeals when denials arrive. Michael Gao co-founded SmarterDx and serves as chief executive officer per the company page reviewed in July 2026. SmarterDx describes itself as clinical AI for revenue integrity and, as of 2026, operates as part of Smarter Technologies according to its website banner.
The company’s October 2024 launch of SmarterDenials extended its platform from pre-bill clinical review into AI-generated appeal letters — a product direction Gao framed as helping hospitals fight a rising tide of payer denials while reducing the hours denials staff spend reconstructing clinical evidence from faxed or mailed denial notices.
What the company does
SmarterDx builds clinical AI that reads patient records to support revenue cycle workflows hospitals historically staffed with manual nurse and coder review. SmarterPrebill analyzes documentation before billing to catch conditions and acuity levels that might otherwise undercode encounters. SmarterDenials, launched October 28, 2024, accepts uploaded denied claims, analyzes the record for evidence supporting the billed service, and produces comprehensive appeal letters with case-specific clinical citations and coding references in minutes rather than hours or days.
SmarterDenials targets complex denial categories including DRG downgrades and level-of-service disputes — denial types where clinical narrative quality determines overturn success rates. The platform combines SmarterDx’s proprietary clinical models for evidence identification with generative AI for letter drafting, a pairing Gao described as giving hospitals tools to respond quickly as payers tighten approval criteria.
Additional modules — SmarterUtilizations, SmarterNotes, and SmarterCharges — extend the same clinical AI foundation across utilization review, documentation support, and charge capture workflows within one platform health systems deploy across more than twenty leading systems cited in the SmarterDenials release.
Who it serves
SmarterDx serves hospital revenue cycle and clinical documentation teams at health systems experiencing denial rate growth and operational disruption from manual appeals processes. University of Arkansas for Medical Sciences chief executive Dr. Cam Patterson quoted in the SmarterDenials announcement described rising denials adversely affecting bottom lines and ultimately patient care investment — a framing SmarterDx uses to connect revenue integrity automation to clinical mission rather than back-office efficiency alone.
Denials teams receiving payer correspondence via fax or traditional mail face reconstruction delays SmarterDenials aims to compress; hospitals spending over twenty billion dollars annually attempting to overturn denials, per SmarterDx’s official release statistics, represent the addressable operational cost the platform targets.
Company background
Gao founded SmarterDx in 2020 in New York, building a clinical AI platform health systems adopted for pre-bill revenue integrity before expanding into post-denial appeals. The company’s evolution into Smarter Technologies reflects broader portfolio consolidation in healthcare AI revenue cycle, though SmarterDx retains its brand and product suite on smarterdx.com.
SmarterDx positions clinical AI expertise — models trained on hospital documentation patterns rather than generic large language models alone — as the differentiator separating its appeals from template-based denials software that lacks patient-specific evidence retrieval.
Product and AI capabilities
SmarterDenials applies SmarterDx’s proprietary clinical AI to identify documentation justifying care provided, then uses generative AI to compose appeal narratives grounded in that evidence. Gao stated the product cuts typical appeal drafting time from hours to minutes while producing letters backed by coding references hospitals can defend with auditors. The dual-model architecture — retrieval plus generation — addresses a common failure mode of raw LLM appeal drafts that cite generic policy language without patient-specific clinical facts.
SmarterPrebill and SmarterDenials are complementary: pre-bill modules reduce initial denial volume while appeals automation improves recovery on denials that still occur — a full revenue integrity loop hospitals evaluate as payer behavior tightens.
Key developments
2020: SmarterDx founded in New York by Michael Gao. October 28, 2024: SmarterDenials AI appeals solution announced (smarterdx.com news, official source). 2026: SmarterDx website indicates membership in Smarter Technologies corporate group.
SmarterDx cited fifteen percent initial claim denial rates and twenty percent denial growth over five years in its SmarterDenials launch materials — statistics framing the market urgency behind 2024 product expansion without relying on third-party industry reports.
Why it matters
SmarterDx matters because payer denials are simultaneously a clinical documentation problem and an operational throughput problem — hospitals cannot hire enough denials nurses to manually compose appeals at scale as denial rates rise. SmarterDenials is a concrete 2024 product showing generative AI entering regulated revenue cycle workflows with clinical evidence grounding rather than unconstrained text generation.
SmarterDx complements point-of-care documentation vendors such as Regard: Regard reduces upstream missed diagnoses while SmarterDx recovers revenue when denials occur anyway. Health systems should evaluate both layers when case mix index and denial overturn rates move in the wrong direction simultaneously.
Sector context
SmarterDx belongs in Brel’s AI in healthcare coverage under healthcare technology and revenue cycle AI, distinct from clinical documentation ambient vendors and distinct from imaging AI. Readers comparing vendors should verify whether appeals products ground generative output in proprietary clinical models or generic LLM templates — evidence retrieval quality determines overturn rates.
Revenue cycle leaders should pilot SmarterDenials on DRG downgrade and level-of-service denial categories first — complex denial types where manual appeal quality varies most across staff and where AI evidence retrieval delivers measurable ROI fastest.
Sources and references
SmarterDenials launch news page (October 28, 2024) and Company leadership page.
- SmarterDx — SmarterDenials launch (smarterdx.com, October 28, 2024)
- SmarterDx — Company / leadership (smarterdx.com)
Reviewed July 10, 2026. Michael Gao is co-founder and CEO. Part of Smarter Technologies per site banner.